Mineralys Therapeutics confirms commercial readiness for lorundrostat ahead of December 22 PDUFA date with cash runway into 2028.
Mineralys Therapeutics (MLYS) outlined commercial launch preparations for lorundrostat during its Q2 2026 earnings call, emphasizing readiness ahead of the December 22, 2026 PDUFA date. The company also highlighted a cash runway extending into 2028, providing financial flexibility for upcoming milestones.
Management focused on evaluating partnering opportunities and advancing clinical development for lorundrostat, its lead asset. The Q2 update follows prior guidance on regulatory timelines and operational execution, with no material changes to earlier projections.
Shares of MLYS remained stable as investors digested the update, reflecting confidence in the company’s regulatory and financial positioning.